Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial
Dean Follmann, Holly Janes, Olive D. Buhule, et al.
Annals of Internal Medicine (2022) Vol. 175, Iss. 9, pp. 1258-1265
Open Access | Times Cited: 106

Showing 1-25 of 106 citing articles:

Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities—workshop report
Jane M. Knisely, Lucas E. Buyon, Rebecca Mandt, et al.
npj Vaccines (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 68
Tracking the COVID-19 vaccines: The global landscape
Tushar Yadav, Swatantra Kumar, Gourav Mishra, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 1
Open Access | Times Cited: 48
Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results
Spyros Chalkias, Jordan L. Whatley, Frank Eder, et al.
Nature Medicine (2023) Vol. 29, Iss. 9, pp. 2325-2333
Open Access | Times Cited: 44
Hybrid immunity-based induction of durable pan-endemic-coronavirus immunity in the elderly
Lucie Loyal, Julian Braun, Ulf Reimer, et al.
Cell Reports (2025) Vol. 44, Iss. 2, pp. 115314-115314
Open Access | Times Cited: 1
Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada
Danuta M. Skowronski, Samantha E Kaweski, Michael A. Irvine, et al.
Canadian Medical Association Journal (2022) Vol. 194, Iss. 47, pp. E1599-E1609
Open Access | Times Cited: 45
Awareness of SARS-CoV-2 Omicron Variant Infection Among Adults With Recent COVID-19 Seropositivity
Sandy Joung, Joseph E. Ebinger, Nancy Sun, et al.
JAMA Network Open (2022) Vol. 5, Iss. 8, pp. e2227241-e2227241
Open Access | Times Cited: 44
How methodological pitfalls have created widespread misunderstanding about long COVID
Tracy Beth Høeg, Shamez Ladhani, Vinay Prasad
BMJ evidence-based medicine (2023) Vol. 29, Iss. 3, pp. 142-146
Open Access | Times Cited: 38
Reconsideration of Antinucleocapsid IgG Antibody as a Marker of SARS-CoV-2 Infection Postvaccination for Mild COVID-19 Patients
Santosh Dhakal, Tong Yu, Anna Yin, et al.
Open Forum Infectious Diseases (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 37
Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial
Ivan T. Lee, Catherine A. Cosgrove, Patrick Moore, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 9, pp. 1007-1019
Open Access | Times Cited: 37
Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens
Shona C. Moore, Barbara Kronsteiner, Stephanie Longet, et al.
Med (2023) Vol. 4, Iss. 3, pp. 191-215.e9
Open Access | Times Cited: 35
Effect of vaccine booster, vaccine type, and hybrid immunity on humoral and cellular immunity against SARS-CoV-2 ancestral strain and Omicron variant sublineages BA.2 and BA.5 among older adults with comorbidities: a cross sectional study
Carol Ho-Yan Fong, Xiaojuan Zhang, Lin-Lei Chen, et al.
EBioMedicine (2023) Vol. 88, pp. 104446-104446
Open Access | Times Cited: 22
SARS-CoV-2 Related Antibody-Dependent Enhancement Phenomena In Vitro and In Vivo
Emi E. Nakayama, Tatsuo Shioda
Microorganisms (2023) Vol. 11, Iss. 4, pp. 1015-1015
Open Access | Times Cited: 21
SARS-CoV-2 Serology and Self-Reported Infection Among Adults — National Health and Nutrition Examination Survey, United States, August 2021–May 2022
Lara J. Akinbami, Deanna Kruszon-Moran, Chia‐Yih Wang, et al.
MMWR Morbidity and Mortality Weekly Report (2022) Vol. 71, Iss. 48, pp. 1522-1525
Open Access | Times Cited: 27
National seroepidemiological study of COVID‐19 after the initial rollout of vaccines: Before and at the peak of the Omicron‐dominant period in Japan
Takeshi Arashiro, Satoru Arai, Ryo Kinoshita, et al.
Influenza and Other Respiratory Viruses (2023) Vol. 17, Iss. 2
Open Access | Times Cited: 18
Prior SARS‐CoV‐2 infection and COVID‐19 vaccine effectiveness against outpatient illness during widespread circulation of SARS‐CoV‐2 Omicron variant, US Flu VE network
Sara Y. Tartof, Fagen Xie, Ruchi Yadav, et al.
Influenza and Other Respiratory Viruses (2023) Vol. 17, Iss. 5
Open Access | Times Cited: 16
Vaccine efficacy of NVX-CoV2373 against SARS-CoV-2 infection in adolescents in the USA: an ancillary study to a phase 3, observer-blinded, randomised, placebo-controlled trial
Meagan E. Deming, Elizabeth R. Brown, Monica A. McArthur, et al.
The Lancet Microbe (2025), pp. 100984-100984
Open Access
Characterising the SARS-CoV-2 nucleocapsid (N) protein antibody response
Charles O. Noble, Ellie McDonald, Suellen Nicholson, et al.
Journal of Infection (2025), pp. 106436-106436
Open Access
Association of infection-induced antibody levels with risk of subsequent SARS–COV-2 reinfection among healthcare professionals, Rhode Island, 1 March 2020–17 February 2021
Jianrong Shi, Myra Gayle Gabriel, Monica Epperson, et al.
Microbiology Spectrum (2025)
Open Access
Discordant Outcomes of SARS-CoV-2 Infection in Household Contacts
Ye‐Ji Lee, Alison Tarke, Tertuliano Alves Pereira Neto, et al.
(2025)
Closed Access
Seroprevalence of SARS-CoV-2 IgG antibodies in children seeking medical care in Seattle, WA June 2020 to December 2022
Amanda L. Adler, Alpana Waghmare, Kirsten Lacombe, et al.
Microbiology Spectrum (2025)
Open Access
Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults
Deborah Theodore, Angela R. Branche, Lily Zhang, et al.
JAMA Network Open (2023) Vol. 6, Iss. 7, pp. e2323349-e2323349
Open Access | Times Cited: 14
Combined anti-S1 and anti-S2 antibodies from hybrid immunity elicit potent cross-variant ADCC against SARS-CoV-2
Michael D. Grant, Kirsten Bentley, Ceri A. Fielding, et al.
JCI Insight (2023) Vol. 8, Iss. 15
Open Access | Times Cited: 13
Enhancing detection of SARS-CoV-2 re-infections using longitudinal sero-monitoring: demonstration of a methodology in a cohort of people experiencing homelessness in Toronto, Canada
Lucie Richard, Rosane Nisenbaum, Karen Colwill, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 4
When Should I Get My Next COVID-19 Vaccine? Data From the Surveillance of Responses to COVID-19 Vaccines in Systemic Immune-Mediated Inflammatory Diseases (SUCCEED) Study
Dawn M. E. Bowdish, Vinod Chandran, Carol Hitchon, et al.
The Journal of Rheumatology (2024) Vol. 51, Iss. 7, pp. 721-727
Open Access | Times Cited: 4
SARS-CoV-2 breakthrough infections enhance T cell response magnitude, breadth, and epitope repertoire
Alison Tarke, Parham Ramezani-Rad, Tertuliano Alves Pereira Neto, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 6, pp. 101583-101583
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top